Company Shakeups

TEVA Gets Taste of Own Medicine

The Israeli generic drug maker, known for its aggressive tactics is getting a taste of its own medicine if Pittsburgh based, Mylan has anything to say about it (I can’t get enough of the: “taste of its own medicine line”).

TEVA markets a proprietary, branded drug for MS called glatiramer acetate (COPAXONE), sold $1.7B worth of the drug last year and is on pace to top $2B this year. The patent doesn’t expire until 2014 but Mylan (after signing an agreement with the India based NATCO) is threating sales in the US, EU, Canada and Japan, among others.

There is still a long road to market due to the whole pesky patent issue, but I’m sure we’ll soon see a challenge and some interesting fireworks.

In conclusion: TEVA gets a taste of its own medicine.

Probably related articles

• FDA unveils plan for approving generic drugs [via CNN]
• Mylan Laboratories names new executives [via Money]
• Merck Licenses Bone Drug for Generic Sale [via NYT]
• Today In Business: Generic Schizophrenia Drug [via NYT]
• Wyeth sues Teva over heartburn drug [via CNN]
• Mylan generic targets Salix staple [via CNN]
• AstraZeneca Settles Ranbaxy Lawsuit [via NYT]

Theoretically Related Posts

• August 15, 2008 -- Wanna Know Why Drug Discovery/Development Is Hard? (0)
• June 19, 2008 -- Sanofi Gets Into Generics Game (0)
• June 2, 2008 -- Fampridine Results Send Acorda Up +20% (0)
• April 21, 2008 -- Disease Briefing: Multiple Sclerosis (0)
• April 16, 2008 -- MS News: Fingolimod (FTY720) Open Label Results and Tysabri PML Data (0)
• June 11, 2008 -- Daiichi Sankyo Goes Generic with Ranbaxy Purchase (0)

© 2008 Pharmababble.